Pharmacogenomic approaches that may guide preeclampsia therapy
| dc.contributor.author | Luizon, Marcelo R. | |
| dc.contributor.author | Sandrim, Valeria C. [UNESP] | |
| dc.contributor.institution | Universidade de São Paulo (USP) | |
| dc.contributor.institution | Universidade Estadual Paulista (Unesp) | |
| dc.date.accessioned | 2014-05-27T11:28:48Z | |
| dc.date.available | 2014-05-27T11:28:48Z | |
| dc.date.issued | 2013-04-01 | |
| dc.description.affiliation | Department of Pharmacology Faculty of Medicine of Ribeirao Preto University of Sao Paulo, Av. Bandeirantes, 3900, 14049-900, Ribeirao Preto, SP | |
| dc.description.affiliation | Department of Pharmacology Institute of Biosciences Universidade Estadual Paulista (UNESP), Botucatu, São Paulo | |
| dc.description.affiliationUnesp | Department of Pharmacology Institute of Biosciences Universidade Estadual Paulista (UNESP), Botucatu, São Paulo | |
| dc.format.extent | 591-593 | |
| dc.identifier | http://dx.doi.org/10.2217/pgs.13.23 | |
| dc.identifier.citation | Pharmacogenomics, v. 14, n. 6, p. 591-593, 2013. | |
| dc.identifier.doi | 10.2217/pgs.13.23 | |
| dc.identifier.issn | 1462-2416 | |
| dc.identifier.issn | 1744-8042 | |
| dc.identifier.scopus | 2-s2.0-84875973410 | |
| dc.identifier.uri | http://hdl.handle.net/11449/75024 | |
| dc.identifier.wos | WOS:000317405300001 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | Pharmacogenomics | |
| dc.relation.ispartofjcr | 2.302 | |
| dc.relation.ispartofsjr | 0,845 | |
| dc.rights.accessRights | Acesso restrito | pt |
| dc.source | Scopus | |
| dc.subject | antihypertensive therapy | |
| dc.subject | epigenetics | |
| dc.subject | epistasis | |
| dc.subject | pharmacogenomics | |
| dc.subject | preeclampsia | |
| dc.subject | atorvastatin | |
| dc.subject | endoglin | |
| dc.subject | hydralazine | |
| dc.subject | labetalol | |
| dc.subject | methyldopa | |
| dc.subject | nifedipine | |
| dc.subject | nitric oxide | |
| dc.subject | vasculotropin receptor 1 | |
| dc.subject | CACNA1A gene | |
| dc.subject | CYP3A5 gene | |
| dc.subject | disease marker | |
| dc.subject | DNA polymorphism | |
| dc.subject | eNOS gene | |
| dc.subject | FLT 1 gene | |
| dc.subject | gene | |
| dc.subject | human | |
| dc.subject | MMP9 gene | |
| dc.subject | personalized medicine | |
| dc.subject | review | |
| dc.subject | treatment outcome | |
| dc.subject | VEGF gene | |
| dc.subject | VEGFR 1 gene | |
| dc.subject | VEGFR 2 gene | |
| dc.title | Pharmacogenomic approaches that may guide preeclampsia therapy | en |
| dc.type | Artigo | pt |
| dcterms.license | http://www.futuremedicine.com/page/terms.jsp | |
| dspace.entity.type | Publication | |
| relation.isOrgUnitOfPublication | ab63624f-c491-4ac7-bd2c-767f17ac838d | |
| relation.isOrgUnitOfPublication.latestForDiscovery | ab63624f-c491-4ac7-bd2c-767f17ac838d | |
| unesp.author.orcid | 0000-0002-6168-7470[2] | |
| unesp.author.orcid | 0000-0002-8331-3525[1] | |
| unesp.campus | Universidade Estadual Paulista (UNESP), Instituto de Biociências, Botucatu | pt |
| unesp.department | Farmacologia - IBB | pt |
